Pharming Group N.V.

NASDAQ
PHAR
paper.types.company
Rentabilité sur six mois: +21.2%
Rendement en dividendes: 0%
Secteur: Healthcare

10.75 $

0 $ 0%
6.82 $
12.16 $

paper.min_max_per_year

Calendrier des promotions Pharming Group N.V.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Pharming Group N.V.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2020-12-23
ISIN
US71716E1055
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 2.42 6
P/BV 3.24 5
P/E 58.02 2
Efficacité
Nom Signification Grade
ROA -2.51 0
ROE -4.92 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA 15.08 0
Debt/Ratio 0.2802 10
Debt/Equity 0.8065 9
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 3.2 1
Rentabilité Ebitda, % -93.59 0
Rentabilité EPS, % -121.32 0
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 10.75 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 11.52 $ 0 $ 0 $ -6.68 % 0 % 0 %
common.calendar.number_days.30d 10.38 $ 10.75 $ 12.16 $ 3.56 % 0 % 0 %
common.calendar.number_days.90d 8.05 $ 7.69 $ 12.16 $ 33.54 % 0 % 0 %
common.calendar.number_days.180d 8.87 $ 7.65 $ 12.16 $ 21.2 % 0 % 0 %
common.calendar.number_days.1y 7.47 $ 6.82 $ 12.16 $ 43.91 % 0 % 0 %
common.calendar.number_days.3y 12.44 $ 6.82 $ 15.98 $ -13.59 % 0 % 0 %
common.calendar.number_days.5y 6.61 $ 6.61 $ 16.7 $ 162.76 % 0 % 0 %
common.calendar.number_days.10y 6.61 $ 6.61 $ 16.7 $ 162.76 % 0 % 0 %
common.calendar.number_days.ytd 8.42 $ 7.65 $ 12.16 $ 27.69 % 0 % 0 %

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Sijmen de Vries M.B.A., M.D. President, CEO & Executive Director 1.44M 1959 (66 années)
Mr. Jeroen Wakkerman Chief Financial Officer N/A 1969 (56 années)
Ms. Mireille Sanders M.Sc. Chief Operations Officer N/A 1968 (57 années)
Susanne Embleton Investor Relations Manager N/A
Mr. Ruud Van Outersterp Chief Ethics & Compliance Officer N/A 1964 (61 année)
Dr. Anurag Relan M.D., MPH Chief Medical Officer N/A 1972 (53 année)
Mr. Stephen Toor Chief Commercial Officer & GM Americas N/A 1971 (54 année)
Dr. Alexander Breidenbach M.B.A. Chief Business Officer N/A 1964 (61 année)
Dr. Bruno M. L. Giannetti Consultant N/A 1952 (73 année)

Informations sur l'entreprise

Adresse: Netherlands, Leiden CR, Darwinweg 24 - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.pharming.com